Condition: Locally Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Acepodia Biotech, Inc.
ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).
This description comes directly from the study's public registry record.
Stephanie Chien · +1 415 366 7822 · clinical@acepodiabio.com
Always discuss trial participation with your own doctor first.
| University of California San Diego | San Diego, California, United States | Recruiting |
| SCRI Denver Drug Development Unit | Denver, Colorado, United States | Recruiting |
| Sarah Cannon Research Institute (SCRI) Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology | Dallas, Texas, United States | Recruiting |
| Taipei Veterans General Hospital | Taipei, Beitou District, Taiwan | Not Yet Recruiting |
| Chang Gung Medical Foundation Linkou | Taoyuan City, Guishan District, Taiwan | Not Yet Recruiting |
| Taipei Medical University-Shuang Ho Hospital | New Taipei City, Zhonghe District, Taiwan | Not Yet Recruiting |
| Mackay Memorial Hospital Taipei | Taipei, Zhongshan District, Taiwan | Not Yet Recruiting |
| Taichung Veteran General Hospital | Taichung, Taiwan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06415487